Palisade Bio (PALI) Enterprise Value (2010 - 2026)
Palisade Bio (PALI) posted quarterly Enterprise Value of -$132.6 million for Q1 2026, down 1734.41% year-over-year from $8.1 million in Q1 2025, and little changed quarter-over-quarter from -$132.4 million in Q4 2025.
Palisade Bio (PALI) Enterprise Value (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Enterprise Value for 17 consecutive years, with -$132.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 1734.41% year-over-year to -$132.6 million; the TTM figure through Mar 2026 stood at -$132.6 million (down 1734.41% YoY), while the FY2025 annual figure was -$132.4 million, down 1256.13% from the prior year.
- Enterprise Value steadied at -$132.6 million in Q1 2026 per PALI's latest filing, from -$132.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.0 million in Q2 2022 and bottomed at -$132.6 million in Q1 2026.
- Historically, Enterprise Value has averaged -$24.6 million across 5 years, with a median of -$11.4 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 60.64% — and 2026, when it sank 1734.41%.
- Palisade Bio's Enterprise Value stood at -$12.4 million in 2022, then fell by 0.4% to -$12.4 million in 2023, then climbed by 21.47% to -$9.8 million in 2024, then slumped by 1256.13% to -$132.4 million in 2025, then retreated by 0.17% to -$132.6 million in 2026.
- Business Quant data shows PALI's Enterprise Value at -$132.6 million in Q1 2026, -$132.4 million in Q4 2025, and -$5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | -125.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -125.20 Mn |
| Mar 31, 2026 | -132.63 Mn |
| Dec 31, 2025 | -132.40 Mn |
| Sep 30, 2025 | -5.23 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Dec 31, 2024 | -9.76 Mn |
| Sep 30, 2024 | -8.04 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -11.28 Mn |
| Dec 31, 2023 | -12.43 Mn |
| Sep 30, 2023 | -15.31 Mn |
| Jun 30, 2023 | -16.40 Mn |
| Mar 31, 2023 | -13.30 Mn |
| Dec 31, 2022 | -12.38 Mn |
| Sep 30, 2022 | -13.99 Mn |
| Jun 30, 2022 | -4.98 Mn |
| Mar 31, 2022 | -6.64 Mn |
| Dec 31, 2021 | -10.50 Mn |
| Sep 30, 2021 | -14.10 Mn |